Telix (TLX) CEO details ADRs, options and large indirect stake

Rhea-AI Filing Summary

Telix Pharmaceuticals Ltd managing director and Group CEO Christian Behrenbruch has filed an initial statement of holdings, detailing his equity and derivative interests in the company. He holds performance share appreciation rights over 93,114 ordinary shares at an exercise price of 4.9500 (Australian dollars) expiring on April 4, 2027, and further rights over 100,223 ordinary shares at 6.9000 expiring on December 31, 2027. These PSARs were granted in April 2022 and May 2023 and are already vested and exercisable.

Behrenbruch also holds share rights over 2,595 ordinary shares at a zero exercise price, expiring on March 31, 2028, which are likewise vested and exercisable. Indirectly, 20,675,000 ordinary shares are held through Elk River Holdings Pty Ltd, where he is the sole director and shareholder. In addition, he directly owns 400,000 American Depositary Receipts, each convertible into one ordinary share with no expiration date, and 254,006 ordinary shares held directly.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Behrenbruch Christian

(Last) (First) (Middle)

C/O TELIX PHARMACEUTICALS LTD

55 FLEMINGTON RD

(Street)

NORTH MELBOURNE 3051

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Telix Pharmaceuticals Ltd [ TLX ]

3a. Foreign Trading Symbol
[TLX]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	MD & Group CEO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	20,675,000	I	Elk River Holdings Pty Ltd(1)
American Depositary Receipts	400,000(2)	D
Ordinary Shares	254,006	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Share Appreciation Rights (right to buy)	(3)	04/04/2027	Ordinary Shares	93,114	$4.95(4)	D
Performance Share Appreciation Rights (right to buy)	(5)	12/31/2027	Ordinary Shares	100,223	$6.9(4)	D
Share Rights	(6)	03/31/2028	Ordinary Shares	2,595	$0	D

Explanation of Responses:

1. Dr. Behrenbruch is the sole director and shareholder of Elk River Holdings Pty Ltd.

2. Each American Depositary Receipt (ADR) is convertible at any time, at the holders election, into one ordinary share of the issuer. The ADRs have no expiration date.

3. The performance share appreciation rights (PSARs) were granted on April 5, 2022 and became vested and exercisable on March 6, 2025.

4. Conversion price is reported in Australian Dollars.

5. The PSARs were granted on May 30, 2023, and became vested and exercisable on March 12, 2026.

6. The share rights were granted on May 21, 2025, and became vested and exercisable on March 5, 2026.

Remarks:

Ex. 24 - Power of Attorney

	/s/ Genevieve Ryan, on behalf of Dr. Christian Behrenbruch, MD & Group CEO	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What equity derivatives in Telix Pharmaceuticals (TLX) does CEO Christian Behrenbruch hold?

Christian Behrenbruch holds performance share appreciation rights over 93,114 ordinary shares at 4.9500 and 100,223 shares at 6.9000, plus share rights over 2,595 shares at zero exercise price, all vested and exercisable with expirations between 2027 and 2028.

How many Telix Pharmaceuticals (TLX) ordinary shares are held indirectly for Christian Behrenbruch?

A total of 20,675,000 Telix ordinary shares are held indirectly through Elk River Holdings Pty Ltd. Footnotes state Behrenbruch is the sole director and shareholder of Elk River, linking this large indirect position to him as part of his overall economic exposure.

What direct Telix Pharmaceuticals (TLX) shareholdings does Christian Behrenbruch report?

Behrenbruch reports direct ownership of 254,006 ordinary shares in Telix Pharmaceuticals. Alongside this, he directly holds 400,000 American Depositary Receipts and several vested rights over additional ordinary shares, giving him meaningful direct equity exposure to the company’s performance.

What American Depositary Receipts (ADRs) in Telix Pharmaceuticals (TLX) does the CEO own?

He directly holds 400,000 Telix American Depositary Receipts. Each ADR is convertible at any time, at the holder’s election, into one ordinary share of Telix Pharmaceuticals, and the ADRs have no expiration date, offering ongoing flexibility for conversion.

When did Christian Behrenbruch’s Telix performance share appreciation rights become exercisable?

One PSAR grant became vested and exercisable on March 6, 2025, and the other on March 12, 2026. These grants, from April 5, 2022 and May 30, 2023, now give him the right to acquire ordinary shares at fixed exercise prices until their expirations.

What are the key terms of Christian Behrenbruch’s Telix share rights?

He holds share rights over 2,595 ordinary shares with an exercise price of 0.0000. These share rights were granted on May 21, 2025, became vested and exercisable on March 5, 2026, and expire on March 31, 2028, enhancing his long-term equity incentives.